Last updated 2026-07-26
- Raised Seed round led by Peregrine Ventures, Nov 2023
- Raised Pre-Seed round led by NFX Capital, Aug 2022
Total raised
—
Last: Undisclosed Round 2023-12
Stage
Seed
Founded
2021
Headcount
8
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences
About
Trojan Bio is an Israeli biotech innovator dedicated to revolutionizing cancer treatment through the development of cutting-edge bi-functional antibodies. Their proprietary platform, based on engineered antibodies, activates the immune system to fight cancer in the same way as common viral infections. Trojan antibodies detect, inhibit, and mark cancer cells as virally infected, signaling the immune system to attack them. The company aims to bridge the immunotherapy gap by offering a promising solution for combating a wide range of cancer types, addressing the low response rates of current immunotherapies.
Funding history · 2 rounds · — total
2023-11
Seed
Undisclosed
★ Peregrine Ventures
2022-08
Pre-Seed
Undisclosed
★ NFX Capital
Headcount over time
From 3 (2022-10) to 6 (2025-12) · +3 (+100%) · 8 points · source: Finder history + radar grounding
Q&A
- What is Trojan Bio's primary focus?
- Trojan Bio is an Israeli biotech company developing a novel immunotherapy modality that utilizes bi-functional antibodies to harness antiviral immunity for combating cancer.
- When was Trojan Bio founded?
- Trojan Bio was founded in October 2021.
- What is the current employee count at Trojan Bio?
- Trojan Bio currently has 1-10 employees.
- Who are the co-founders of Trojan Bio?
- The co-founders of Trojan Bio are Anat Burkovitz (CEO & Co-Founder) and Amir Aharoni (Co-Founder and R&D).
- What is Trojan Bio's current funding stage?
- Trojan Bio is currently in the Seed funding stage.
- What is the core technology behind Trojan Bio's approach?
- Trojan Bio's proprietary platform is based on engineered bi-functional antibodies that detect, inhibit, and mark cancer cells as virally infected, signaling the immune system to attack them.
- In which sector does Trojan Bio primarily operate?
- Trojan Bio operates primarily in the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Does Trojan Bio hold any patents?
- Yes, Trojan Bio holds one patent.
Team · 2
Anat Burkovitz
Founder · CEO & Co-Founder
Amir Aharoni
Founder · Co-Founder and R&D
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
cancerclinicspharmaceuticalsimmuno-theraphycancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | trojan-bio.com/ |
|---|---|
| linkedin.com/company/82642561 |
Identifiers & details
| Legal name | TrojanBio Ltd |
|---|---|
| Founded | 2021-10 |
| Employees (exact) | 8 |
Radar intelligence
Patents
| EPO | 3 |
|---|
Web history (Wayback)
| Domain | trojan-bio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516471208 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2021-10-05 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | דרך אילות 10 גני תקווה |